Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.

Palamà IE, Coluccia AM, Gigli G.

Nanomedicine (Lond). 2014 Jul;9(14):2087-98. doi: 10.2217/nnm.13.147. Epub 2013 Dec 23.

PMID:
24364873
2.

Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.

Palamà IE, Leporatti S, de Luca E, Di Renzo N, Maffia M, Gambacorti-Passerini C, Rinaldi R, Gigli G, Cingolani R, Coluccia AM.

Nanomedicine (Lond). 2010 Apr;5(3):419-31. doi: 10.2217/nnm.10.8.

PMID:
20394535
3.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

4.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

5.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
6.

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.

Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P.

Mol Cancer Ther. 2013 Jun;12(6):1085-98. doi: 10.1158/1535-7163.MCT-12-0550. Epub 2013 Mar 27.

7.

New strategies in controlling drug resistance in chronic myeloid leukemia.

Frame D.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. Review.

PMID:
18056927
8.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
9.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

10.

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P.

Blood. 2006 Feb 15;107(4):1591-8. Epub 2005 Oct 25.

11.

[Tyrosine kinase inhibitors for the treatment of CML].

Heim D.

Ther Umsch. 2006 Apr;63(4):249-54. Review. German.

PMID:
16689455
12.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

13.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.

Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.

Leukemia. 2005 Oct;19(10):1774-82.

PMID:
16136169
14.

[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].

Usui N.

Rinsho Byori. 2004 Feb;52(2):136-44. Review. Japanese.

PMID:
15027317
15.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Lee J, Shen P, Zhang G, Wu X, Zhang X.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.

PMID:
23201011
16.

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F.

Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8.

PMID:
21198861
17.

Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.

Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CHM, Wang JYJ, Naoe T.

Int J Hematol. 2008 Dec;88(5):471-475. doi: 10.1007/s12185-008-0221-1. Epub 2008 Nov 29.

18.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

19.

Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.

PMID:
22397755
20.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.

Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV.

Leukemia. 2004 Aug;18(8):1352-6.

PMID:
15201856

Supplemental Content

Support Center